Date | Price Target | Rating | Analyst |
---|---|---|---|
3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
MONTVALE, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the HC Wainwright & Co. 26th Annual Global Investment Conference on September 9, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solut
MONTVALE, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal second quarter ended June 30, 2024. The Company reported quarterly net sales of $234.1 million, quarterly net earnings of $32.1 million, adjusted EBITDA(a) of $62.3 million, and free cash flow(a) of $38.4 million. Ted Harris, Chairman, President and CEO of Balchem said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth." Second Qu
MONTVALE, N.J., July 12, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, July 26, 2024, at 11:00 AM Eastern Time (ET) to review second quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Friday, July 26, 2024. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), fi
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
4 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
10-Q - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
Avian influenza, also known as bird flu, has public health officials on alert after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year. A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported. Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia. Most of the human cases have come from exposure t
As of July 9, 2024, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Balchem Corp (NASDAQ:BCPC) On May 3, Balchem posted better-than-expected first-quarter results.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for BJ’s Restaurants, Inc. (NASDAQ:BJRI) from $40 to $43. Wedbush analyst Nick Setyan maintained an Outperform rating. BJ’s Restaurants shares rose 5.9% to close at $34.68 on Friday. See how other analysts view this stock. Mizuho boosted the price target for Robinhood Markets, Inc (NASDAQ:HOOD) from $20 to $21. Mizuho analyst Dan Dolev maintained a Buy rating. Robinhood shares rose 1.9% to close at $17.95 on Friday. See how other analysts view this stock. B of A
MONTVALE, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal second quarter ended June 30, 2024. The Company reported quarterly net sales of $234.1 million, quarterly net earnings of $32.1 million, adjusted EBITDA(a) of $62.3 million, and free cash flow(a) of $38.4 million. Ted Harris, Chairman, President and CEO of Balchem said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth." Second Qu
MONTVALE, N.J., July 12, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, July 26, 2024, at 11:00 AM Eastern Time (ET) to review second quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Friday, July 26, 2024. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), fi
MONTVALE, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of $239.7 million, quarterly net earnings of $29.0 million, adjusted EBITDA(a) of $60.9 million, and free cash flow(a) of $26.8 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and net earnings, as well as solid first quarter cash flows, despite the continued challenging environment in parts of our portfolio." First Quarter 2024 Financial Hig